Cargando…
Therapeutic Potential of Intrabodies for Cancer Immunotherapy: Current Status and Future Directions
Tumor cells are characterized by overexpressed tumor-associated antigens or mutated neoantigens, which are expressed on the cell surface or intracellularly. One strategy of cancer immunotherapy is to target cell-surface-expressed tumor-associated antigens (TAAs) with therapeutic antibodies. For targ...
Autor principal: | Böldicke, Thomas |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9326752/ https://www.ncbi.nlm.nih.gov/pubmed/35892709 http://dx.doi.org/10.3390/antib11030049 |
Ejemplares similares
-
Specific in vivo knockdown of protein function by intrabodies
por: Marschall, Andrea LJ, et al.
Publicado: (2015) -
Current status and future directions of cancer immunotherapy
por: Zhang, Hongming, et al.
Publicado: (2018) -
Molecular cloning and characterization of a novel anti-TLR9 intrabody
por: Reimer, Elisa, et al.
Publicado: (2013) -
Intrabodies against the Polysialyltransferases ST8SiaII and ST8SiaIV inhibit Polysialylation of NCAM in rhabdomyosarcoma tumor cells
por: Somplatzki, Stefan, et al.
Publicado: (2017) -
ER intrabody-mediated inhibition of interferon α secretion by mouse macrophages and dendritic cells
por: Büssow, Konrad, et al.
Publicado: (2019)